drugset / Trial / NCT06406205

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

NCT06406205

Phase 3 Recruiting 270 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy of QL1074 compared with placebo in achieving renal response after 52 weeks of therapy in subjects with Active Lupus Nephritis.

Timeline

Start
2023-12-25
Primary completion
2027-06
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Voclosporin Other / unclassified 23.7 mg Oral

Indications